Publications by authors named "L Gold"
Tapinarof cream 1% once daily (QD) demonstrated significant efficacy in patients down to age 2 years with atopic dermatitis (AD) in the ADORING 1 and 2 phase 3 trials. We report local tolerability outcomes. Patients received Tapinarof or vehicle cream QD for 8 weeks.
View Article and Find Full Text PDFIntroduction: Traumatic injury is the leading cause of pediatric mortality and morbidity in the United States. While behavioral impairments of children after traumatic brain injury (TBI) have been described, outcomes following traumatic spinal cord injury (SCI) and multi-trauma (MT) are less known. We aimed to address the prevalence of behavioral and neuropsychiatric disorders in pediatric and adolescent trauma patients.
View Article and Find Full Text PDFBackground: Psoriasis is a chronic inflammatory skin disease often associated with obesity. Psoriasis therapies may be less effective in patients with obese. The purpose of this expert consensus panel is to evaluate the relationship between obesity and efficacy of psoriasis therapies, thereby optimizing patient care.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the effects of using gabapentin alongside opioids compared to tricyclic antidepressants (TCAs) or duloxetine with opioids in older adults with spine-related issues.
- Researchers analyzed data from 134,266 Medicare beneficiaries, focusing on mortality rates and major medical complications from 2017 to 2019.
- They found no significant difference in mortality between the two groups, but those on gabapentin and opioids had a slightly higher risk of major medical complications.
Article Synopsis
- Topical clindamycin phosphate/adapalene/benzoyl peroxide (CAB) gel is approved for treating acne in patients 12 and older, and post hoc analyses examined its effectiveness in younger patients with acne.
- Data from two studies showed that CAB significantly improved treatment success and reduced acne lesions in adolescents compared to a vehicle gel, with 51.5% of treated adolescents achieving success versus 24.9% with the vehicle.
- The CAB gel was generally well tolerated, with most adverse events being mild to moderate, and it was effective for younger children as well, with significant lesion reductions observed in all treated children.